207 related articles for article (PubMed ID: 6127032)
1. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
Taffet SL; Das KM
Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
[TBL] [Abstract][Full Text] [Related]
2. Desensitization for sulfasalazine skin rash.
Purdy BH; Philips DM; Summers RW
Ann Intern Med; 1984 Apr; 100(4):512-4. PubMed ID: 6142671
[TBL] [Abstract][Full Text] [Related]
3. Drug therapy of inflammatory bowel disease.
Sack DM; Peppercorn MA
Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
[TBL] [Abstract][Full Text] [Related]
4. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
Korelitz BI; Present DH; Rubin PH; Fochios SE
J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
[TBL] [Abstract][Full Text] [Related]
5. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
Eitner K; Reinicke C; Hippius M
Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
[TBL] [Abstract][Full Text] [Related]
6. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
Eitner K; Hippius M; Reinicke C
Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
[TBL] [Abstract][Full Text] [Related]
7. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
[No Abstract] [Full Text] [Related]
8. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
Das KM
Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
[TBL] [Abstract][Full Text] [Related]
9. Desensitization for sulfasalazine-induced skin rash in a patient with ulcerative colitis.
Akahoshi K; Chijiiwa Y; Kabemura T; Okabe H; Akamine Y; Nawata H
J Gastroenterol; 1994 Dec; 29(6):772-5. PubMed ID: 7874275
[TBL] [Abstract][Full Text] [Related]
10. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
Das KM; Eastwood MA
Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
[TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
Tolia V
Am J Gastroenterol; 1992 Aug; 87(8):1029-32. PubMed ID: 1353658
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
Klotz U; Maier K; Fischer C; Heinkel K
N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
[TBL] [Abstract][Full Text] [Related]
13. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
Goldstein PD; Alpers DH; Keating JP
J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
[TBL] [Abstract][Full Text] [Related]
14. Compliance to therapy in patients on a maintenance dose of sulfasalazine.
van Hees PA; van Tongeren JH
J Clin Gastroenterol; 1982 Aug; 4(4):333-6. PubMed ID: 6126499
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects with oral 5-aminosalicyclic acid.
Fardy JM; Lloyd DA; Reynolds RP
J Clin Gastroenterol; 1988 Dec; 10(6):635-7. PubMed ID: 2906645
[TBL] [Abstract][Full Text] [Related]
16. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.
Peppercorn MA
Ann Intern Med; 1984 Sep; 101(3):377-86. PubMed ID: 6147110
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature.
Yamakado S; Yoshida Y; Yamada T; Kishida T; Kobayashi M; Nomura T
Intern Med; 1992 Jan; 31(1):108-13. PubMed ID: 1348965
[TBL] [Abstract][Full Text] [Related]
18. Hemolysis during salicylazosulfapyridine therapy.
van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH
Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
Das KM; Eastwood MA; McManus JP; Sircus W
N Engl J Med; 1973 Sep; 289(10):491-5. PubMed ID: 4146729
[No Abstract] [Full Text] [Related]
[Next] [New Search]
